REstore Working Ability in RheumatoiD Arthritis

Summary

The purpose of the study is to assess whether a 6-month treatment with adalimumab added on the treatment with conventional antirheumatic drugs (DMARD) will decrease the number of days on sick leave compared to placebo. In addition, the cost-effectiveness and cost-utility of the intervention compared to the conventional treatment is evaluated, and the patients who benefit most are characterized.

Timeline

Start

2011-05

Primary completion

2012-12

Completion

2013-03

Drugs

Indications